Forest Laboratories has posted a strong set of third-quarter results, which show that sales climbed 14% to $795 million, versus the sale period last year [[21/01/04c]], while net income was up 15% to $261 million or $0.70 per share – in line with expectations [[06/01/05c]]
Read MoreOxford BioMedica’s share price rose an impressive 22% on the London Stock Exchange this morning after the UK company confirmed that it had been approached by a third party and was holding merger discussions.
Read MoreAbbott Laboratories says that fourth quarter earnings were in line with expectations [[15/10/04a]], rising by just over 3% to $975 million dollars, on the back of a 15% hike in sales versus the same period last year to $4.9 billion as its rheumatoid arthritis offering, Humira (adalimumab), continued to put in a strong showing [[19/01/04b]]. The latter product, which hit the US markets following its launch in 2003 [[06/01/03g]], brought in revenues of some $852 million during the three-month period – up 79% on last year – prompting the company to up its full-year 2005 sales forecast for the product to in excess of $1.3 billion [[12/07/04a]].
Read MoreUS drugmaker, Wyeth, has moved a step closer toward settling thousands of lawsuits brought by patients claiming to have suffered heart damage as a result of taking its obesity drugs in the 1990s.
Read MoreUS biotechnology company, Allergan, received a boost yesterday as investors welcomed the firm’s announcement that it would be restructuring its European operations, saving as much as $9 million dollars per year in the process.
Read More
